10/17/2026
Federal Healthcare and FDA Enforcement Developments in October 2026
What healthcare providers and peptide businesses should understand about recent federal enforcement
By Richard A. Merlino, P.A.
October 17, 2026
Federal healthcare and Food and Drug Administration enforcement developments reported between October 2 and October 16, 2026, underscore the value of early legal review. Recent actions address research-use-only marketing, laboratory testing, Medicare billing, pharmacy practices, and the movement of business proceeds. New Department of Justice policies also affect when prosecutors seek asset restraints and where companies should direct voluntary disclosures.
For a healthcare business or peptide seller facing scrutiny, the practical concern is how the records connect a particular person to the conduct being investigated. Website language, customer messages, physician orders, testing data, and responses to complaints can become central evidence. The defense observations that follow are analysis of the cited developments, not predictions about the outcome of another case.
Research use only labels must be evaluated alongside the sales record
An October 6 DEA report describes Ryan Fields’s September 18 jury conviction for conspiracy involving misbranded or unapproved drugs and smuggling, and for money-laundering conspiracy. According to the government’s account, his websites used research-only disclaimers while emails and Facebook posts described human health benefits and dosing. The jury also ordered forfeiture of a residence and vehicle purchased with proceeds. [1]
The case illustrates why counsel must review the complete sales record. A disclaimer’s wording should be examined together with customer communications, purchasing restrictions, and the conduct attributed to the seller. Preserve historical versions of those materials so that later edits do not obscure what appeared during the relevant period.
The reported verdict does not establish that every RUO transaction is criminal. A defense assessment must address the actual products, intended-use evidence, the elements of the alleged offenses, and each person’s knowledge and participation. The financial allegations also warrant a separate examination of proceeds and the connection between transactions and property sought for forfeiture.
DOJ is directing prosecutors to address assets earlier
DOJ’s October 8 announcement of Directive 26-13 describes a broader approach to fraud investigations, including healthcare and pharmaceutical matters. The directive, dated October 7, calls for evaluating additional tax exposure, using early asset seizures and injunctions, developing proactive cooperators, and strengthening sentencing advocacy. [2]
This policy makes financial preparation especially important at the investigative stage. Counsel should identify ownership interests, document the sources of funds, and assess which assets the government may contend are connected to alleged misconduct. Third-party ownership and legitimate business receipts require a clear factual record. A business also needs to understand how a restraint could affect its ability to operate and respond to the investigation.
The directive states prosecutorial priorities. It does not itself create new seizure authority or remove the legal requirements governing a particular restraint. The defense must examine the government’s asserted authority and evidence rather than assume that an announced enforcement priority resolves those questions.
A new disclosure policy changes where companies should report
On October 15, DOJ and HHS-OIG announced a coordinated policy for corporate disclosures of potential criminal healthcare conduct. Under the announced policy, a qualifying disclosure affecting a federal healthcare program to the Fraud Division’s Health Care Fraud Section receives the benefits of OIG’s Self-Disclosure Protocol without a separate OIG portal submission. Disclosure only to OIG generally does not constitute voluntary disclosure to DOJ. [3]
The recipient and sequence of a disclosure therefore deserve attention before a company submits an account of suspected misconduct. Counsel should determine the nature of the potential violation, investigate the facts sufficiently to assess available options, and evaluate eligibility, cooperation, and remediation requirements. Any independent reporting obligation must also be addressed.
Coordinating the submission process does not make disclosure a risk-free decision. Corporate benefits should not be treated as immunity for owners or employees, and their interests may require separate consideration. The announcement is agency policy, not a judicial ruling that guarantees a particular resolution.
A South Florida verdict shows the importance of orders and complaints
DOJ’s October 7 release reports Joseph Rodriguez’s October 6 conviction in the Southern District of Florida for conspiracy and six substantive healthcare-fraud counts. The government described unnecessary blood tests added to COVID-testing events, claims using a physician’s name without the required orders, and complaints from patients, a physician, and community managers. It reported more than $15 million billed to Medicare and more than $500,000 paid. [4]
The practical lesson for laboratory and marketing cases is to reconstruct the workflow. What was offered to the patient? Who authorized each test? Who prepared the claim? Who received complaints, and what happened afterward? The answers can help distinguish an administrative problem from evidence of knowing participation in a scheme.
The billed and paid figures also require separate treatment. Counsel should examine the evidentiary and legal basis for the government’s proposed sentencing-loss calculation rather than allow a headline billing total to substitute for that analysis. A trial verdict is a case outcome; the announcement supplies no new binding Eleventh Circuit rule.
FDA is examining both production controls and the data supporting certificates
Two FDA letters connect product-quality concerns to the reliability of the underlying records. The Pine Pharmaceuticals letter, dated August 7 and posted October 6, criticizes aseptic practices, particulate investigations, and corrective responses that relied on passing tests or an absence of adverse events without adequately demonstrating process corrections. [5]
For a compounder, a corrective-action response should explain the identified cause, the changes made, and the evidence showing those changes work. Training records, validation, and effectiveness checks can help substantiate the response. Counsel should identify the actual statutory and regulatory requirements and distinguish them from draft-guidance expectations.
The Eurofins SF Analytical Laboratories letter, dated October 6 and posted October 13, addresses selective omission of unfavorable microbial results, compromised testing plates, and inadequate assessment of whether customer certificates of analysis contained incomplete or inaccurate information. FDA also questioned the reliability of retrospective conclusions drawn from deficient records. [6]
For businesses relying on outside testing, a certificate is the starting point for investigation. Obtain the underlying results, methods, deviations, and communications needed to assess what the certificate supports. Identify when the customer learned of any limitation and how it responded. A laboratory’s failure and a customer’s knowing misconduct are different factual questions.
These letters communicate FDA’s enforcement positions concerning the recipients. They are not criminal convictions or independent proof of another company’s wrongdoing. Their value to defense preparation lies in identifying the records and explanations that may be tested during an investigation.
The CVS settlement connects dispensing policies with reimbursement exposure
On October 13, DOJ announced that CVS and related entities agreed to pay $315 million to resolve allegations involving unlawful controlled-substance dispensing and federal reimbursement. The government alleged ignored prescription warning signs and corporate staffing, performance, and incentive policies that contributed to the conduct. DEA-related remedial measures include monitoring and reporting processes. The release expressly states that the settlement resolves allegations without a determination of liability. [7]
For pharmacies, the defense record should include the policies in effect, staffing conditions, pharmacist escalations, prescriber reviews, and the disposition of identified concerns. The existence of a written compliance policy alone may not explain how a challenged prescription was handled.
Individual knowledge also requires separate attention. Corporate directives, a pharmacist’s actual information, and the evidence supporting particular reimbursement claims should be examined on their own facts. A civil settlement does not establish criminal guilt, and suspicious patterns do not eliminate the need to prove the elements of an offense.
Nominal ownership and later transfers can create separate exposure
On October 13, the New Hampshire U.S. Attorney’s Office reported Leo Anzivino Jr.’s guilty plea to money-laundering conspiracy involving a Medicare equipment supplier. The government described nominal ownership, false ownership certifications, beneficiary returns, banking warnings, and subsequent transfers. It reported more than $6 million in Medicare claims and more than $3 million paid. [8]
A person described as a nominee or owner on paper needs an assessment extending beyond the title. Counsel should reconstruct actual control, access to accounts, compensation, communications with the beneficial owners, and knowledge at the time of each challenged transfer. Messages and transactions after warnings may be particularly consequential.
This plea does not establish liability merely from nominal ownership. It does demonstrate why enrollment paperwork, bank certifications, and payment activity belong in the initial review of a healthcare business investigation.
Preparing a defense before the record becomes harder to reconstruct
Across these developments, early preparation begins with preserving the original records and establishing a reliable chronology. Marketing materials should be tied to their publication dates. Complaints should be tied to their recipients and responses. Testing certificates should be connected to the data they summarize, and financial transfers to the people who authorized them.
For Florida healthcare providers, laboratories, pharmacies, and peptide businesses, the central task is to understand the government’s theory precisely enough to test it. Regulatory concerns, civil allegations, and criminal charges involve different legal standards. A focused investigation allows counsel to challenge unsupported inferences, address genuine compliance problems, and evaluate disclosure or resolution options with a clearer understanding of the evidence.
Primary sources
[1] DEA report on Ryan Fields conviction
October 6, 2026; verdict September 18, 2026
[2] DOJ announcement of Directive 26 13
October 8, 2026; directive dated October 7, 2026
[3] DOJ and HHS OIG coordinated healthcare self disclosure policy
October 15, 2026
[4] DOJ report on Joseph Rodriguez conviction
October 7, 2026; verdict October 6, 2026
[5] FDA warning letter to Pine Pharmaceuticals
August 7, 2026; posted October 6, 2026
[6] FDA warning letter to Eurofins SF Analytical Laboratories
October 6, 2026; posted October 13, 2026
[7] DOJ announcement of CVS civil settlement
October 13, 2026; updated October 14, 2026
[8] DOJ report on Leo Anzivino Jr guilty plea
October 13, 2026
This article discusses developments reported from October 2 through October 16, 2026. It provides general information and defense analysis, not legal advice for a particular matter. Agency accounts summarize the government’s position; the underlying case record and applicable law govern any individual assessment.
